VFMAP predicted hepatocellular carcinoma development in patients with chronic hepatitis C who were treated with direct-acting antiviral and achieved sustained virologic response.

IF 1.9 4区医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Journal of Medical Ultrasonics Pub Date : 2024-04-01 Epub Date: 2023-12-26 DOI:10.1007/s10396-023-01398-5

Tomomitsu Matono, Toshifumi Tada, Takashi Nishimura, Tomoyuki Takashima, Nobuhiro Aizawa, Naoto Ikeda, Hideyuki Shiomi, Hirayuki Enomoto, Hiroko Iijima

{"title":"VFMAP predicted hepatocellular carcinoma development in patients with chronic hepatitis C who were treated with direct-acting antiviral and achieved sustained virologic response.","authors":"Tomomitsu Matono, Toshifumi Tada, Takashi Nishimura, Tomoyuki Takashima, Nobuhiro Aizawa, Naoto Ikeda, Hideyuki Shiomi, Hirayuki Enomoto, Hiroko Iijima","doi":"10.1007/s10396-023-01398-5","DOIUrl":null,"url":null,"abstract":"Purpose: Risk factors for the development of hepatocellular carcinoma (HCC) remain unclear in patients with hepatitis C virus (HCV) who achieve sustained virological response (SVR) after direct-acting antiviral (DAA) therapy. This study investigated the usefulness of the VFMAP scoring system for predicting the development of HCC in these patients.Methods: This study included 358 patients with HCV who achieved SVR after DAA treatment. The VFMAP system defines and scores cutoff values for virtual touch quantification (VTQ), fasting plasma glucose, sex, age, and alpha-fetoprotein values. All patients were grouped according to their VFMAP scores as follows: 0 or 1 point, low-score group; 2 or 3 points, intermediate-score group; and 4 or 5 points, high-score group.Results: Nineteen patients developed HCC. The median follow-up duration was 3.2 (1.5-4.0) years. The respective cumulative incidence rates of HCC at 12, 24, and 36 months were as follows in different subgroups: all study patients, 3.0%, 4.8%, and 6.6%; low-score group, 0.96%, 0.96%, and 0.96%; intermediate-score group, 2.6%, 4.5%, and 6.8%; and high-score group, 10.0%, 15.3%, and 18.5%. The cumulative incidence rates of HCC in the high-score group were significantly higher than those in the low- and intermediate-score groups (p < 0.001 and < 0.05, respectively).Conclusion: VFMAP accurately predicted the development of HCC in HCV patients who achieved SVR following treatment with DAAs.","PeriodicalId":50130,"journal":{"name":"Journal of Medical Ultrasonics","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medical Ultrasonics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10396-023-01398-5","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/12/26 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Risk factors for the development of hepatocellular carcinoma (HCC) remain unclear in patients with hepatitis C virus (HCV) who achieve sustained virological response (SVR) after direct-acting antiviral (DAA) therapy. This study investigated the usefulness of the VFMAP scoring system for predicting the development of HCC in these patients.

Methods: This study included 358 patients with HCV who achieved SVR after DAA treatment. The VFMAP system defines and scores cutoff values for virtual touch quantification (VTQ), fasting plasma glucose, sex, age, and alpha-fetoprotein values. All patients were grouped according to their VFMAP scores as follows: 0 or 1 point, low-score group; 2 or 3 points, intermediate-score group; and 4 or 5 points, high-score group.

Results: Nineteen patients developed HCC. The median follow-up duration was 3.2 (1.5-4.0) years. The respective cumulative incidence rates of HCC at 12, 24, and 36 months were as follows in different subgroups: all study patients, 3.0%, 4.8%, and 6.6%; low-score group, 0.96%, 0.96%, and 0.96%; intermediate-score group, 2.6%, 4.5%, and 6.8%; and high-score group, 10.0%, 15.3%, and 18.5%. The cumulative incidence rates of HCC in the high-score group were significantly higher than those in the low- and intermediate-score groups (p < 0.001 and < 0.05, respectively).

Conclusion: VFMAP accurately predicted the development of HCC in HCV patients who achieved SVR following treatment with DAAs.

查看原文本刊更多论文

VFMAP 可预测接受直接作用抗病毒治疗并获得持续病毒学应答的慢性丙型肝炎患者的肝细胞癌发展情况。

目的：直接作用抗病毒药物（DAA）治疗后获得持续病毒学应答（SVR）的丙型肝炎病毒（HCV）患者发生肝细胞癌（HCC）的风险因素仍不明确。本研究探讨了 VFMAP 评分系统预测这些患者发生 HCC 的有用性：本研究纳入了 358 名在接受 DAA 治疗后获得 SVR 的 HCV 患者。VFMAP 系统定义了虚拟触诊定量（VTQ）、空腹血浆葡萄糖、性别、年龄和甲胎蛋白值的临界值并对其进行评分。所有患者根据其 VFMAP 分数分组如下：0或1分，低分组；2或3分，中分组；4或5分，高分组：19名患者发展为HCC。中位随访时间为 3.2（1.5-4.0）年。不同亚组在 12 个月、24 个月和 36 个月时的 HCC 累计发病率分别为：所有研究患者，3.0%、4.8% 和 6.6%；低分组，0.96%、0.96% 和 0.96%；中分组，2.6%、4.5% 和 6.8%；高分组，10.0%、15.3% 和 18.5%。高分组的 HCC 累计发病率明显高于低分组和中分组的（P 结论：VFMAP 能准确预测 HCC 的发病率：VFMAP能准确预测接受DAAs治疗后获得SVR的HCV患者发生HCC的情况。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Medical Ultrasonics 医学-核医学

CiteScore

3.30

自引率

11.10%

发文量

102

审稿时长

>12 weeks

期刊介绍： The Journal of Medical Ultrasonics is the official journal of the Japan Society of Ultrasonics in Medicine. The main purpose of the journal is to provide forum for the publication of papers documenting recent advances and new developments in the entire field of ultrasound in medicine and biology, encompassing both the medical and the engineering aspects of the science.The journal welcomes original articles, review articles, images, and letters to the editor.The journal also provides state-of-the-art information such as announcements from the boards and the committees of the society.